{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:19:59Z","timestamp":1778948399085,"version":"3.51.4"},"reference-count":79,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR40188\/BTIS\/137\/27\/2021"],"award-info":[{"award-number":["BT\/PR40188\/BTIS\/137\/27\/2021"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Drug repurposing has emerged as an important strategy and it has a great potential in identifying therapeutic applications for COVID-19. An extensive virtual screening of 4193 FDA approved drugs has been carried out against 24 proteins of SARS-CoV2 (NSP1-10 and NSP12-16, envelope, membrane, nucleoprotein, spike, ORF3a, ORF6, ORF7a, ORF8, and ORF9b). The drugs were classified into top 10 and bottom 10 drugs based on the docking scores followed by the distribution of their therapeutic indications. As a result, the top 10 drugs were found to have therapeutic indications for cancer, pain, neurological disorders, and viral and bacterial diseases. As drug resistance is one of the major challenges in antiviral drug discovery, polypharmacology and network pharmacology approaches were employed in the study to identify drugs interacting with multiple targets and drugs such as dihydroergotamine, ergotamine, bisdequalinium chloride, midostaurin, temoporfin, tirilazad, and venetoclax were identified among the multi-targeting drugs. Further, a pathway analysis of the genes related to the multi-targeting drugs was carried which provides insight into the mechanism of drugs and identifying targetable genes and biological pathways involved in SARS-CoV2.<\/jats:p>","DOI":"10.1371\/journal.pone.0289890","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T17:33:44Z","timestamp":1691602424000},"page":"e0289890","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Polypharmacology guided drug repositioning approach for SARS-CoV2"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-7178","authenticated-orcid":true,"given":"Esther","family":"Jamir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himakshi","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lipsa","family":"Priyadarsinee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikrusenuo","family":"Kiewhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selvaraman","family":"Nagamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Narahari","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"pone.0289890.ref001","unstructured":"Coronavirus Disease Situation Reports (WHO) [Accessed in February, 2022]."},{"key":"pone.0289890.ref002","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"N Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0289890.ref003","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"SF Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"pone.0289890.ref004","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1099\/vir.0.19302-0","article-title":"The origin of the 1918 pandemic influenza virus: a continuing enigma","volume":"84","author":"AH Reid","year":"2003","journal-title":"J Gen Virol"},{"key":"pone.0289890.ref005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cca.2020.05.044","article-title":"COVID-19: Transmission, prevention, and potential therapeutic opportunities","volume":"508","author":"M Lotfi","year":"2020","journal-title":"Clin Chim Acta"},{"key":"pone.0289890.ref006","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"C Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pone.0289890.ref007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7150\/ijms.51935","article-title":"Perspective Adjunctive Therapies for COVID-19: Beyond antiviral therapy","volume":"18","author":"P Ho","year":"2021","journal-title":"Int J Med Sci"},{"key":"pone.0289890.ref008","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infection: A randomized clinical trial","volume":"3","author":"MGS Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0289890.ref009","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","volume":"26","author":"E Chorin","year":"2020","journal-title":"Nat Med"},{"key":"pone.0289890.ref010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/v13030439","article-title":"Structure-function analyses of new SARS-CoV-2 variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, diagnostic, therapeutic and public health implications","volume":"13","author":"J Singh","year":"2021","journal-title":"Viruses"},{"key":"pone.0289890.ref011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s42003-021-01754-6","article-title":"Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants","volume":"4","author":"R Wang","year":"2021","journal-title":"Commun Biol"},{"key":"pone.0289890.ref012","doi-asserted-by":"crossref","first-page":"166725","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"R Arya","year":"2021","journal-title":"J Mol Biol"},{"key":"pone.0289890.ref013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s43141-021-00152-z","article-title":"Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics","volume":"19","author":"MU Hossain","year":"2021","journal-title":"J Genet Eng Biotechnol"},{"key":"pone.0289890.ref014","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000515417","article-title":"Evolution of SARS-CoV-2: Review of mutations, role of the host immune system","volume":"145","author":"H. Banoun","year":"2021","journal-title":"Nephron"},{"key":"pone.0289890.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"AR Fehr","year":"2015","journal-title":"Methods Mol Biol"},{"key":"pone.0289890.ref016","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jmv.25762","article-title":"The establishment of reference sequence for SARS-CoV-2 and variation analysis","volume":"92","author":"C Wang","year":"2020","journal-title":"J Med Virol"},{"key":"pone.0289890.ref017","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","article-title":"The architecture of SARS-CoV-2 transcriptome","volume":"181","author":"D Kim","year":"2020","journal-title":"Cell"},{"key":"pone.0289890.ref018","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2013.11.006","article-title":"SARS-CoV ORF1b-encoded nonstructural proteins 12\u201316: replicative enzymes as antiviral targets","volume":"101","author":"L Subissi","year":"2014","journal-title":"Antiviral Res"},{"key":"pone.0289890.ref019","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"D Schoeman","year":"2019","journal-title":"Virol J"},{"key":"pone.0289890.ref020","doi-asserted-by":"crossref","first-page":"708264","DOI":"10.3389\/fimmu.2021.708264","article-title":"SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns","volume":"12","author":"N Redondo","year":"2021","journal-title":"Front Immunol"},{"key":"pone.0289890.ref021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Z Jin","year":"2020","journal-title":"Nature"},{"key":"pone.0289890.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV2 and its complexes with non-covalent inhibitors","volume":"12","author":"J Osipiuk","year":"2021","journal-title":"Nat. Commun"},{"key":"pone.0289890.ref023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"C Liu","year":"2020","journal-title":"ACS Cent Sci"},{"key":"pone.0289890.ref024","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12250-020-00204-7","article-title":"Old weapon for new enemy: Drug repurposing for treatment of newly emerging viral diseases","volume":"35","author":"D. Guo","year":"2020","journal-title":"Virol Sin"},{"key":"pone.0289890.ref025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.2021.1114","article-title":"SARS-CoV2 vaccines and the growing threat of viral variants","volume":"325","author":"JP Moore","year":"2021","journal-title":"Jama"},{"key":"pone.0289890.ref026","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1007\/s00894-012-1416-1","article-title":"FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking protocols","volume":"18","author":"MH Bohari","year":"2012","journal-title":"J Mol Model"},{"key":"pone.0289890.ref027","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/1062936X.2017.1398782","article-title":"A QSAR and molecular modelling study towards new lead finding: polypharmacological approach to Mycobacterium tuberculosis","volume":"28","author":"S Janardhan","year":"2017","journal-title":"SAR QSAR Environ. Res"},{"key":"pone.0289890.ref028","first-page":"1","article-title":"Repurposing of approved drug molecules for viral infectious diseases: a molecular modelling approach","author":"N Kumar","year":"2021","journal-title":"J Biomol. Struct"},{"issue":"7","key":"pone.0289890.ref029","doi-asserted-by":"crossref","first-page":"e0235030sss","DOI":"10.1371\/journal.pone.0235030","article-title":"In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation","volume":"15","author":"MI Choudhary","year":"2020","journal-title":"PLoS One"},{"key":"pone.0289890.ref030","doi-asserted-by":"crossref","first-page":"200276","DOI":"10.1183\/20734735.0276-2020","article-title":"Length of remdesivir treatment in patients with severe COVID-19","volume":"17","author":"M Ippolito","year":"2021","journal-title":"Breathe (Sheff)"},{"issue":"5","key":"pone.0289890.ref031","doi-asserted-by":"crossref","first-page":"e0267095","DOI":"10.1371\/journal.pone.0267095","article-title":"Discovery of new drug indications for COVID-19: A drug repurposing approach","volume":"17","author":"P Kumari","year":"2022","journal-title":"PLoS One"},{"key":"pone.0289890.ref032","first-page":"e11132","article-title":"Cardiac adverse events with remdesivir in COVID-19 infection","volume":"12","author":"AK Gupta","year":"2020","journal-title":"Cureus"},{"key":"pone.0289890.ref033","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s11030-021-10296-2","article-title":"Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach","volume":"26","author":"S.S Madugula","year":"2021","journal-title":"Mol Diversity"},{"issue":"10","key":"pone.0289890.ref034","doi-asserted-by":"crossref","first-page":"e0240149","DOI":"10.1371\/journal.pone.0240149","article-title":"In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm","volume":"15","author":"L Artigas","year":"2020","journal-title":"PLoS One"},{"key":"pone.0289890.ref035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12039-022-02046-0","article-title":"Applying polypharmacology approach for drug repurposing for SARS-CoV2","volume":"134","author":"E Jamir","year":"2022","journal-title":"J Chem Sci"},{"key":"pone.0289890.ref036","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1021\/ci500737b","article-title":"Dynamics based pharmacophore models for screening potential inhibitors of mycobacterial cyclopropane synthase","volume":"55","author":"C Choudhury","year":"2015","journal-title":"J Chem Inf Model"},{"key":"pone.0289890.ref037","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/138920307781369427","article-title":"Virtual screening in drug discovery\u2014a computational perspective","volume":"4","author":"AS Reddy","year":"2007","journal-title":"Curr Protein Pept Sci"},{"key":"pone.0289890.ref038","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2174\/138620711797537102","article-title":"Virtual high throughput screening in new lead identification","volume":"14","author":"P Badrinarayan","year":"2011","journal-title":"Comb Chem High Throughput Screen"},{"key":"pone.0289890.ref039","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ejmech.2007.06.009","article-title":"Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking","volume":"43","author":"GK Ravindra","year":"2008","journal-title":"Eur J Med Chem"},{"key":"pone.0289890.ref040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jmgm.2007.01.007","article-title":"Molecular modeling studies of pyridopurinone derivatives\u2014potential phosphodiesterase 5 inhibitors","volume":"26","author":"P Srivani","year":"2007","journal-title":"J Mol Graph Model"},{"key":"pone.0289890.ref041","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nsb1203-980","article-title":"Nakamura H Announcing the worldwide protein data bank","volume":"10","author":"H Berman","year":"2003","journal-title":"Nat Struct Mol Biol"},{"key":"pone.0289890.ref042","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"A Waterhouse","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"pone.0289890.ref043","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"O Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"D1","key":"pone.0289890.ref044","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"DS Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"pone.0289890.ref045","doi-asserted-by":"crossref","first-page":"D932","DOI":"10.1093\/nar\/gkw993","article-title":"DrugCentral: online drug compendium","volume":"45","author":"O Ursu","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"pone.0289890.ref046","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1093\/bioinformatics\/btaa1005","article-title":"DeepPurpose: a deep learning library for drug-target interaction prediction","volume":"36","author":"K Huang","year":"2021","journal-title":"Bioinformatics"},{"key":"pone.0289890.ref047","doi-asserted-by":"crossref","first-page":"W270","DOI":"10.1093\/nar\/gkr366","article-title":"SwissDock, a protein-small molecule docking web service based on EADock DSS","volume":"39","author":"A Grosdidier","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"pone.0289890.ref048","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1186\/1471-2105-12-S1-S33","article-title":"iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis","volume":"12","author":"KC Hsu","year":"2011","journal-title":"BMC Bioinform"},{"issue":"11","key":"pone.0289890.ref049","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/v12111325","article-title":"Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model","volume":"12","author":"Y Choi","journal-title":"Viruses"},{"key":"pone.0289890.ref050","doi-asserted-by":"crossref","first-page":"153317","DOI":"10.1016\/j.phymed.2020.153317","article-title":"Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication","volume":"85","author":"S Kumar","year":"2021","journal-title":"Phytomedicine"},{"key":"pone.0289890.ref051","doi-asserted-by":"crossref","first-page":"613401","DOI":"10.3389\/fmolb.2020.613401","article-title":"Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro","volume":"7","author":"S Vincent","year":"2020","journal-title":"Front Mol Biosci"},{"key":"pone.0289890.ref052","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","volume":"178","author":"A Shannon","year":"2020","journal-title":"Antiviral Res"},{"key":"pone.0289890.ref053","doi-asserted-by":"crossref","first-page":"106012","DOI":"10.1016\/j.ijantimicag.2020.106012","article-title":"Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking","volume":"56","author":"R Yu","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"50","key":"pone.0289890.ref054","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1021\/acs.jpcb.0c07312","article-title":"Remdesivir strongly binds to both RNA-dependent RNA polymerase and main protease of SARS-CoV-2: Evidence from molecular simulations","volume":"124","author":"HL Nguyen","year":"2020","journal-title":"J Phys Chem B"},{"key":"pone.0289890.ref055","doi-asserted-by":"crossref","first-page":"6772","DOI":"10.1080\/07391102.2020.1802346","article-title":"In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials","volume":"39","author":"S Gul","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"pone.0289890.ref056","first-page":"1","article-title":"Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease","volume":"23","author":"S Ghosh","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"pone.0289890.ref057","doi-asserted-by":"crossref","first-page":"106749","DOI":"10.1016\/j.intimp.2020.106749","article-title":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19","volume":"86","author":"X Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"pone.0289890.ref058","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(20)30270-X","article-title":"Baricitinib for COVID-19: a suitable treatment?\u2014Authors\u2019 reply","volume":"20","author":"PJ Richardson","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0289890.ref059","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1574886317666220328155207","article-title":"Use of Polypharmacy and Emergence of COVID-19 Variants\u2014Are they Co-Related?","volume":"18","author":"M Agarwal","year":"2023","journal-title":"Curr Drug Saf."},{"issue":"19","key":"pone.0289890.ref060","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"A Anighoro","year":"2014","journal-title":"J Med Chem"},{"key":"pone.0289890.ref061","first-page":"536","article-title":"Structure-function relationships among selected human coronaviruses","volume":"59","author":"E Jamir","year":"2022","journal-title":"Indian J Biochem Biophys"},{"key":"pone.0289890.ref062","doi-asserted-by":"crossref","first-page":"111544","DOI":"10.1016\/j.biopha.2021.111544","article-title":"Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach","volume":"138","author":"Z Molavi","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"pone.0289890.ref063","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/1389203718666161108091609","article-title":"Drug-Target Interactions: Prediction Methods and Applications","volume":"19","author":"S Anusuya","year":"2018","journal-title":"Curr Protein Pept Sci"},{"issue":"10","key":"pone.0289890.ref064","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1039\/C7MD00381A","article-title":"A systematic analysis of atomic protein-ligand interactions in the PDB","volume":"8","author":"R Ferreira de Freitas","year":"2017","journal-title":"Medchemcomm"},{"issue":"5","key":"pone.0289890.ref065","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1021\/cr500344e","article-title":"Cooperativity in Noncovalent Interactions","volume":"116","author":"AS Mahadevi","year":"2016","journal-title":"Chem Rev"},{"issue":"44","key":"pone.0289890.ref066","doi-asserted-by":"crossref","first-page":"13257","DOI":"10.1021\/ja027200q","article-title":"Comparison of various types of hydrogen bonds involving aromatic amino acids","volume":"124","author":"S Scheiner","year":"2002","journal-title":"J Am Chem Soc"},{"issue":"2","key":"pone.0289890.ref067","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/ci4005354","article-title":"Pathway analysis for drug repositioning based on public database mining","volume":"54","author":"Y Pan","year":"2014","journal-title":"J Chem Inf Model"},{"issue":"16","key":"pone.0289890.ref068","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/bioinformatics\/btl334","article-title":"Additional gene ontology structure for improved biological reasoning","volume":"22","author":"S Myhre","year":"2006","journal-title":"Bioinformatics"},{"issue":"1","key":"pone.0289890.ref069","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s43141-022-00388-3","article-title":"The consequences of viral infection on host DNA damage response: a focus on SARS-CoVs","volume":"20","author":"AS Mekawy","year":"2022","journal-title":"J Genet Eng Biotechnol"},{"issue":"1","key":"pone.0289890.ref070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pharmrev.120.000180","article-title":"Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins","volume":"75","author":"IB Kotliar","year":"2023","journal-title":"Pharmacol Rev"},{"issue":"3","key":"pone.0289890.ref071","doi-asserted-by":"crossref","first-page":"L430","DOI":"10.1152\/ajplung.00499.2020","article-title":"SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport","volume":"320","author":"R Abdel Hameid","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5","key":"pone.0289890.ref072","first-page":"305","article-title":"Role of membranes in disease","volume":"4","author":"DM Goldberg","year":"1986","journal-title":"Clin Physiol Biochem"},{"key":"pone.0289890.ref073","doi-asserted-by":"crossref","first-page":"630242","DOI":"10.3389\/fcell.2021.630242","article-title":"Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens","volume":"9","author":"Y Deng","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"pone.0289890.ref074","doi-asserted-by":"crossref","first-page":"152021","DOI":"10.1016\/j.imbio.2020.152021","article-title":"SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19","volume":"226","author":"TC Dakal","year":"2021","journal-title":"Immunobiology"},{"issue":"1","key":"pone.0289890.ref075","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Y Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"pone.0289890.ref076","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1200\/CCI.20.00059","article-title":"Improving Cancer Data Interoperability: The Promise of the Minimal Common Oncology Data Elements (mCODE) Initiative","volume":"4","author":"TJ Osterman","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"pone.0289890.ref077","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/2159-8290.CD-21-0144","article-title":"Repurposing of anticancer drugs expands possibilities for antiviral and anti-Inflammatory discovery in COVID-19","volume":"11","author":"M Aldea","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"pone.0289890.ref078","doi-asserted-by":"crossref","first-page":"645216","DOI":"10.3389\/fmolb.2021.645216","article-title":"Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2","volume":"9","author":"T Kumar D","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"47","key":"pone.0289890.ref079","doi-asserted-by":"crossref","first-page":"10641","DOI":"10.1021\/acs.jpcb.0c06747","article-title":"Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study","volume":"124","author":"PD Wakchaure","year":"2020","journal-title":"J Phys Chem B"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0289890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T20:06:36Z","timestamp":1702929996000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0289890"}},"subtitle":[],"editor":[{"given":"Chandrabose","family":"Selvaraj","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":79,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0289890","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]}}}